Want to see HK:0574 full AI Analyst Report?
Top Page
Pa Shun International Holdings Limited
(0574)
Select Model
Select Model
Rating:39Underperform
Price Target:
HK$0.02
▼(-66.00% Downside)
Action:Reiterated
Date:06/26/26
The score is primarily weighed down by very weak financial performance—persistent negative equity, recurring losses, and consistently negative free cash flow. Technicals add further downside risk with a clear downtrend and bearish momentum, while valuation is only slightly better but still constrained by loss-making earnings and no indicated dividend support.
Positive Factors
Debt Reduction
Lower debt than in 2023 is a constructive balance-sheet development and could reduce financing pressure over time. However, the benefit is limited because equity remains negative and leverage is still difficult to assess, so financial flexibility remains constrained.
Negative Factors
Persistent Negative Equity
Persistent negative shareholders’ equity is a major solvency warning because liabilities exceed the reported asset base attributable to shareholders. It limits financial flexibility, makes leverage harder to interpret, and leaves the company more exposed if losses or funding needs continue.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
Lower debt than in 2023 is a constructive balance-sheet development and could reduce financing pressure over time. However, the benefit is limited because equity remains negative and leverage is still difficult to assess, so financial flexibility remains constrained.
Read all positive factors
Pa Shun International Holdings Limited (0574) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$39.82M
Dividend Yield7.65%
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth0.21%
EPS Growth-2.33%
CountryHK
Employees108
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,212,489,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.16
Price to Book (P/B)-0.36
Price to Sales (P/S)0.61
P/FCF Ratio-4.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pa Shun International Holdings Limited Business Overview & Revenue Model
Company Description
Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, ...
Pa Shun International Holdings Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 86.81M | 86.55M | 129.43M | 71.78M | 85.91M |
| Gross Profit | 12.01M | 17.06M | 29.43M | 13.30M | 11.06M |
| EBITDA | 7.48M | 2.89M | 19.65M | -3.26M | -11.85M |
| Net Income | -15.86M | -15.31M | 2.35M | -43.38M | -330.40M |
Balance Sheet | |||||
| Total Assets | 169.78M | 179.65M | 206.57M | 136.09M | 468.59M |
| Cash, Cash Equivalents and Short-Term Investments | 5.53M | 15.97M | 16.51M | 1.90M | 2.27M |
| Total Debt | 45.48M | 44.03M | 165.97M | 108.71M | 99.01M |
| Total Liabilities | 297.34M | 315.68M | 322.67M | 251.60M | 251.59M |
| Stockholders Equity | -148.04M | -136.04M | -116.10M | -115.52M | -58.50M |
Cash Flow | |||||
| Free Cash Flow | -11.71M | -1.77M | -35.00M | -2.35M | -22.12M |
| Operating Cash Flow | -10.57M | -1.68M | -34.93M | -2.32M | -21.89M |
| Investing Cash Flow | -1.15M | -88.00K | -65.00K | 2.98M | 24.97M |
| Financing Cash Flow | 1.54M | 1.23M | 49.61M | -1.02M | -6.07M |
Pa Shun International Holdings Limited Technical Analysis
Negative
0.05
Price Trends
0.02
Positive
0.03
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
35.65
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0574, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 35.65 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0574.
Pa Shun International Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$779.10M | 7.81 | 13.59% | 7.40% | 10.63% | 39.44% | |
77 Outperform | HK$4.99B | 10.39 | 11.60% | 6.20% | -20.79% | -30.04% | |
65 Neutral | HK$724.27M | 4.75 | 7.52% | 3.70% | 7.05% | 22.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$219.30M | -5.96 | -8.05% | 2.26% | 12.89% | -2.56% | |
49 Neutral | HK$339.89M | 84.72 | 0.34% | 84.69% | -8.30% | -44.44% | |
39 Underperform | HK$39.82M | -1.44 | 10.70% | 7.65% | 0.21% | -2.33% |
* Healthcare Sector Average
HK:0574
Pa Shun International Holdings Limited
0.02
-0.02
-47.06%
HK:3613
Beijing Tong Ren Tang Chinese Medicine Co
5.98
-2.65
-30.71%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.06
-37.42%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.04
-10.29%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.22
-0.81
-39.91%
HK:0239
Pak Fah Yeow International Limited
2.50
0.23
10.33%
Pa Shun International Holdings Limited Corporate Events
Pa Shun Faces Winding-Up Petition Over Unpaid HK$8 Million Loan
Sep 1, 2026
Pa Shun International Holdings Limited has disclosed that a creditor has filed a winding-up petition in the Hong Kong High Court over the company’s failure to repay a HK$8 million loan, plus accrued interest, that was taken for general worki...
Pa Shun Flags Delay in 2026 Interim Results as Receivers Control PRC Units
Aug 24, 2026
Pa Shun International Holdings Limited has warned that it will miss the statutory deadlines for publishing its interim results and sending its interim report for the six months to 30 June 2026, after receivers took control of its PRC subsidiaries ...
Pa Shun International’s Requisitioned EGM Dissolved as Share Trading Remains Suspended
Jul 21, 2026
Pa Shun International Holdings Limited, a Cayman Islands-incorporated investment holding company listed in Hong Kong under stock code 574, is overseen by a board led by Chairman and executive director Yuan Hongbing alongside two independent non-ex...
Pa Shun International warned on trading resumption and potential delisting risk
Jul 16, 2026
Pa Shun International Holdings has disclosed that the Stock Exchange of Hong Kong has issued formal resumption guidance setting out conditions that must be met before trading in the company’s shares can restart. The exchange is requiring the...
Pa Shun International Shareholders Approve All AGM Resolutions Amid Director Vote Imbalance
Jul 7, 2026
Pa Shun International Holdings Limited reported that all resolutions put to shareholders at its adjourned annual general meeting on 7 July 2026 were approved by poll. Shareholders representing about 59% of the company’s issued share capital ...
Pa Shun International Clarifies Board and Committee Structure
Jul 7, 2026
Pa Shun International Holdings Limited has disclosed an updated list of its directors and clarified their respective roles and functions on the board. The company confirms that its board comprises one executive director, chairman Yuan Hongbing, an...
Pa Shun Faces Receivership Over Key Pharma Assets After Scheme Default
Jul 2, 2026
Pa Shun International Holdings has defaulted on a HK$10 million yearly payment due under its court-sanctioned scheme of arrangement, triggering enforcement of a debenture secured over assets of its key pharmaceutical subsidiary. The scheme, which ...
Pa Shun International Halts Trading Pending Inside Information Announcement
Jul 2, 2026
Pa Shun International Holdings Limited, a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange under stock code 574, has a board composed of executive, non-executive and independent non-executive directors in line with typica...
Pa Shun International Adjourns AGM After Lack of Quorum, Resets for July 7
Jun 30, 2026
Pa Shun International Holdings Limited has adjourned its annual general meeting originally scheduled for June 30, 2026, after failing to reach a quorum within the first 30 minutes as required under its articles of association. The meeting has been...
Pa Shun International’s Shareholder-Requisitioned EGM Dissolved for Lack of Quorum
Jun 26, 2026
Pa Shun International Holdings Limited, a Cayman Islands-incorporated company listed in Hong Kong, maintains a board composed of executive, non-executive and independent non-executive directors, consistent with governance norms for listed entities...
Pa Shun International Faces Winding-Up Petition Over HK$8 Million Loan Default
Jun 26, 2026
Pa Shun International Holdings Limited has disclosed that a creditor, Underdog Consulting Limited, has filed a winding-up petition in the Hong Kong High Court, alleging the company failed to repay a HK$8 million loan principal that fell due in Nov...
Pa Shun International Raises HK$6.49 Million in Undersubscribed Rights Issue, Boosting Controlling Stake
Jun 17, 2026
Pa Shun International Holdings has completed a rights issue on the basis of one rights share for every two shares held, raising gross proceeds of about HK$6.99 million, with net proceeds of approximately HK$6.49 million earmarked for partial repay...
Pa Shun International Unveils Board and Committee Structure
Jun 16, 2026
Pa Shun International Holdings Limited has announced the current composition of its board of directors, led by executive director and chairman Yuan Hongbing, alongside a mix of non-executive and independent non-executive directors. The company als...
Pa Shun International CEO Ma Qinghai Resigns Citing Other Commitments
Jun 16, 2026
Pa Shun International Holdings Limited announced that executive director and chief executive officer Mr. Ma Qinghai has resigned, effective 16 June 2026, citing other business commitments requiring greater attention. Mr. Ma stated he has no disagr...
Pa Shun Adds Board Re‑election Resolution to 2026 AGM Agenda
Jun 16, 2026
Pa Shun International Holdings has issued a supplemental notice to its upcoming annual general meeting in Hong Kong, adding a resolution to re-elect Mr. Fang Shuai as a non-executive director. The meeting will be held on 30 June 2026, with arrange...
Pa Shun International Calls 2026 AGM, Seeks Share Issue Mandate and Board Re-elections
Jun 8, 2026
Pa Shun International Holdings Limited has convened its annual general meeting for 30 June 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and the accomp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.